RE:RE:RE:RE:Can we hit 60 000 patients by 2022?It is important to take a grain of salt when considering anything the company says. Sure the sector has a lot of potentials which is evident in the number of contacts they are able to sign, but competition is growing fast with better technologies and seasoned professional management team. If indeed it is taken by a bigger player, I would say it is welcoming news to the current shareholders.